Riley Bove, MD
Internal Medicine · San Francisco, CANPI 1053516625
Payments from drug & device makers
Across 267 payments — averaging $13,533 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$2M
- Genentech, Inc.$669K
- Hoffmann-la Roche Limited$362K
- Biogen$272K
- Novartis$61K
- Sanofi$47K
- plus $224K from 14 others
Across 40 payments — averaging $989.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$34K
- Novartis$3K
- Biogen$2K
- Novartis Pharma AG$798
What the payments were for
- Consulting fees$198,88370%
- Speaking & faculty fees$46,73016%
- Travel & lodging$29,30510%
- Food & beverage$5,0142%
- Education$3,3501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 21 | $1,978,604 |
| Genentech, Inc. | 16 | $668,893 |
| Hoffmann-la Roche Limited | 46 | $361,581 |
| Biogen | 5 | $272,196 |
| Novartis | 9 | $61,387 |
| Sanofi | 16 | $47,175 |
| EMD Serono, Inc. | 26 | $44,918 |
| TG Therapeutics, Inc. | 35 | $33,758 |
| Merck Kgaa | 7 | $32,450 |
| Lilly USA, LLC | 2 | $21,275 |
| AstraZeneca | 26 | $20,844 |
| Amgen(2 entities) | 19 | $20,303 |
| Novartis Pharma AG | 9 | $19,622 |
| Genentech USA, Inc. | 19 | $19,415 |
| Merck Healthcare Kgaa | 1 | $3,780 |
| Sanofi-aventis U.S. LLC | 3 | $3,524 |
| Janssen Research & Development, LLC | 1 | $2,000 |
| Janssen Global Services, LLC | 1 | $1,320 |
| Bristol Myers Squibb | 4 | $304 |
| AbbVie | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$30,581
- BRIUMVI$28,115
- AUBAGIO$27,529
- UPLIZNA$19,988
- OMB157G_ARZERRA_HEMATOLOGY$17,093
- SOLIRIS$15,332
- Rebif$6,344
- Non-Covered Product$5,347
- Evobrutinib$2,250
- KESIMPTA$2,248
- Ponvory$1,320
- Gonal-f$190
- Mavenclad$143
How this compares
$3,613,374 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dalfampridine ErDalfampridine | 15 | $6,152 |
| Teriflunomide | 20 | $2,240 |
| Gabapentin | 23 | $434 |
| Baclofen | 19 | $347 |
| Modafinil | 14 | $324 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
- John FahySan Francisco$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.